UC researchers find protein that mediates formation of HER2-driven breast cancer

(University of Cincinnati Academic Health Center) Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionAlthough well tolerated, the efficacy of everolimus and vinorelbine combination therapy was not superior to vinorelbine monotherapy. There was no correlation between PI3  K mutational status and efficacy.EudracCT No 2011-001024-38, ClinicalTrials.gov No NCT01520103
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractTrace amine-associated receptors are G protein-coupled receptors of which TAAR1 is the most well-studied. Recently, Vattai et al. (J Cancer Res Clin Oncol 143:1637 –1647https://doi.org/10.1007/s00432-017-2420-8,2017) reported that expression of TAAR1 may be a marker of breast cancer (BC) survival, with a positive correlation also suggested between TAAR1 expression and HER2 positivity. Neither a role for TAAR1 in breast tissue, nor in cancer, had previously been suspected. We, therefore, sought to provide independent validation and to further examine these putative relationships. First, a bioinformatic analysi...
Source: Histochemistry and Cell Biology - Category: Biomedical Science Source Type: research
ConclusionSNB application after PST for breast cancer in node positive patients at presentation is increasing. Pre-operative axillary imaging and tumour biology help identify patients who might be candidates for SNB as a single staging procedure.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 18 May 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Zoran CuligAbstractEpithelial to mesencyhmal transition (EMT) has a central role in tumor metastasis and progression. EMT is regulated by several growth factors and pro-inflammatory cytokines. The most important role in this regulation could be attributed to transforming growth factor-β (TGF-β). In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 – extracellular-re...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Opinion statementOral inhibitors of CDK4/6 have been shown to increase response rates and prolong disease control when combined with endocrine therapy in hormone-responsive (HR+) HER2-negative advanced breast cancer. Palbociclib, ribociclib and abemaciclib are all approved in combination with non-steroidal aromatase inhibitors in first-line therapy for post-menopausal women, with a 40 –45% improvement in progression-free survival seen with the addition of any of these CDK4/6 inhibitors. Additional approved indications, including first- and second-line combination therapy for pre-menopausal women, combination with ful...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
AbstractBreast cancer (BC) is a health problem worldwide; there is evidence that inflammatory cytokines are increased in BC. Macrophage migration inhibitory factor (MIF) has multiple effects on immune cells, inflammation and cancer. Besides, in previous studies, contradictory and uncertain results have been presented on the implication of Th17 cytokine profile in BC. The aim of this study was to evaluate the plasma levels of MIF and the Th17 cytokine profile in BC and their association with their molecular subtypes and clinical stage. A total of 150 women with BC of Ella Binational Breast Cancer Study and 60 healthy women ...
Source: Clinical and Experimental Medicine - Category: Research Source Type: research
Condition:   HER2-positive Breast Cancer Intervention:   Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003. Sponsors:   Shanghai Pharmaceuticals Holding Co., Ltd;   Shanghai Jiaolian Medicine Research and Development Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The immunotherapy has revolutionized the world of oncology in the last decades with considerable advantages in terms of overall survival in cancer patients. The association of Pembrolizumab and Trastuzumab was recently proposed in clinical trials for the treatment of Trastuzumab-resistant advanced HER2-positive breast cancer. Although immunotherapies are frequently associated with a wide spectrum of immune-related adverse events, the cardiac toxicity has not been properly studied.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
British Journal of Cancer, Published online: 17 May 2019; doi:10.1038/s41416-019-0473-yA phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Academia | Breast Cancer | Cancer | Cancer & Oncology | HER2